This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The primary endpoint will evaluate the difference in weight loss of nimacimab ...

Skye Bioscience (SKYE) announced preliminary data from a diet-induced obesity model in mice. Skye’s CB1-inhibiting antibody, nimacimab, ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean miceDose-response demonstrated for a range of 5 to 80 ...

Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...

Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

CB1 receptor antagonists, such as the aforementioned rimonabant and taranabant, were found to regulate food intake and adipose tissue metabolism, resulting in weight loss and favorable blood lipid ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean mice Dose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO mice Semaglutide treatment ...

CRB-913 brain levels are 15-fold lower than monlunabant in lean mice Dose-response demonstrated for a range of 5 to 80 mg/kg/day achieving up to 38% weight loss in DIO mice ... its highly peripherally ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

This means that it could be used in combination with GLP-1s to possibly enhance weight loss or simply offer an alternative to these drugs. Second, and one reason why someone might choose a CB1 drug ...